Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Intangibles (2024 - 2025)

BridgeBio Pharma's Change in Intangibles history spans 2 years, with the latest figure at $2.4 million for Q3 2025.

  • For Q3 2025, Change in Intangibles rose 50.47% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $8.5 million, up 6.52%, while the annual FY2025 figure was $8.5 million, 6.52% up from the prior year.
  • Change in Intangibles for Q3 2025 was $2.4 million at BridgeBio Pharma, down from $4.5 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $4.5 million in Q2 2025 and bottomed at $797000.0 in Q1 2024.